NCT06896396View on ClinicalTrials.gov

Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

February 1, 2028

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Lenvatinib, Pembrolizumab

Pabilizumab: intravenously every three weeks Lenvatinib, with a dosage based on body weight: 8 mg (≤60 kg) or 12 mg (\>60 kg), once daily

DRUG

Icaritin soft capsules

Starting 3-5 days after the first TACE treatment, take 6 capsules orally, twice a day, and swallow them with warm water within 30 minutes after breakfast and dinner

PROCEDURE

TACE

TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).

Trial Locations (1)

430030

Tongji Hospital, Wuhan

All Listed Sponsors
lead

Zhiyong Huang

OTHER

NCT06896396 - Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter